Your browser doesn't support javascript.
loading
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich, Romain; Allavena, Clotilde; Peytavin, Gilles; Soulie, Cathia; Tubiana, Roland; Weiss, Laurence; Montoya Ferrer, Ana; Duvivier, Claudine; Bouchaud, Olivier; Bottero, Julie; Durand, Aurore; Lê, Minh-Patrick; Marcelin, Anne-Geneviève; Dudoit, Yasmine; Assoumou, Lambert; Katlama, Christine.
Afiliación
  • Palich R; Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France.
  • Allavena C; Infectious Diseases department, University hospital, INSERM CIC 1413, Nantes, France.
  • Peytavin G; AP-HP, Pharmacology-Toxicology department, Bichat-Claude Bernard hospital, Paris, France.
  • Soulie C; INSERM, UMR1137, IAME, Université de Paris, Paris, France.
  • Tubiana R; Sorbonne University, Virology department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France.
  • Weiss L; Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France.
  • Montoya Ferrer A; Paris Descartes University, Clinical Immunology department, Georges Pompidou hospital, AP-HP, INSERM 976, Paris, France.
  • Duvivier C; Infectious Diseases department, University hospital, Montpellier, France.
  • Bouchaud O; University of Paris, Infectious Diseases department, Necker-Pasteur Infectiology Center, Necker hospital, AP-HP, INSERM 1016, IHU imagine, Paris, France.
  • Bottero J; Infectious Diseases department, Avicenne hospital, AP-HP, Paris, France.
  • Durand A; Infectious Diseases department, Jean Verdier hospital, Paris, France.
  • Lê MP; Sorbonne University, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France.
  • Marcelin AG; AP-HP, Pharmacology-Toxicology department, Bichat-Claude Bernard hospital, Paris, France.
  • Dudoit Y; INSERM, UMR_S 1144, Université de Paris, Paris, France.
  • Assoumou L; AP-HP, Pharmacology-Toxicology department, Bichat-Claude Bernard hospital, Paris, France.
  • Katlama C; Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France.
J Antimicrob Chemother ; 76(2): 477-481, 2021 01 19.
Article en En | MEDLINE | ID: mdl-33099638
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Fármacos Anti-VIH Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Humans / Middle aged Idioma: En Revista: J Antimicrob Chemother Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Fármacos Anti-VIH Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Humans / Middle aged Idioma: En Revista: J Antimicrob Chemother Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido